To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC0651 | Antileishmanial-24c |
Novel antileishmanial agent, strongly inhibiting recombinant CYP51 from L. donovani, displaying activity against L. donovani intracellular amastigotes with an IC50 value of 0.53 μM
More description
|
|
| DCC0650 | Antileishmanial Agent 4 |
Novel antileishmanial agent against L. amazonensis promastigotes (IC 50 = 15.52 ± 3.782 μM) and intracellular amastigotes (IC 50 = 4.10 ± 1.136 μM), 50% cytotoxicity concentration at 84.01 ± 3.064 μM against BALB/c peritoneal macrophages, and 20.49-fold s
More description
|
|
| DCC0649 | Antifungal Cpd 94 |
Novel antifungal agent, inhibiting C. neoformans growth at submicromolar levels, being effective against fluconazole-resistant C. neoformans and a clinical strain of C. gattii, and being not antagonistic with currently approved antifungal
More description
|
|
| DCC0648 | Antifungal Agent C38 |
Novel broad-spectrum antifungal agent, also exhibiting good fungicidal activity against both fluconazole-sensitive and -resistant Candida albicans cells and having potent inhibition activity against Candida albicans biofilm formation and hyphal growth, in
More description
|
|
| DCC0647 | Antifolate C2 |
Novel inhibitor of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter (PCFT) over the reduced folate carrier (RFC)
More description
|
|
| DCC0646 | Antifolate C1 |
Novel inhibitor of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter (PCFT) over the reduced folate carrier (RFC)
More description
|
|
| DCC0645 | Anti-cancer Toxin-1 |
Novel covalent anti-cancer toxin, targeting β-tubulin and covalently modifyng Cys239 within the colchicine binding site
More description
|
|
| DCC0644 | Anticancer Agent-i |
Novel anticancer agent, showing most significant anti-cancer activity against prostate cancer cells with IC50 values of 8.8 µM and 9.5 µM in PC-3 and DU-145 cells, respectively
More description
|
|
| DCC0643 | Antibiotic Adjuvant P35 |
Novel Potent and Nontoxic Antibiotic Adjuvant
More description
|
|
| DCC0642 | Antibacterial Additive 2ai |
Analogue of the marine sponge natural product oroidin, suppresses biofilm formation and enhancing control of copper-resistant Xanthomonas euvesicatoria on pepper
More description
|
|
| DCC0641 | Antiangiogenic Agent G5 |
Novel dose-dependent antiangiogenic agent
More description
|
|
| DCC0640 | Antiallergic Agent 36 |
Novel highly potent orally bioavailable antiallergic agent, effectively suppressing mast cell degranulation in a dose-dependent manner (IC50, 2.54 nM for RBL-2H3 cells; 48.28 nM for peritoneal mast cells (PMCs))
More description
|
|
| DCC0639 | Anti-ad-23e |
Novel multitarget directed anti-Alzheimer agent, showing an IC 50 value of 0.56 ± 0.02 μM for AChE and an IC 50 value of 1.17 ± 0.09 μM for BuChE
More description
|
|
| DCC0638 | Anti-ad Compound L1 |
Novel anti-AD agent, integrating Aβ-interacting and metal-binding fragments in a single molecular framework, exhibiting significant antioxidant activity and metal chelating ability, and also rescuing neuroblastoma N2A cells from Cu -induced Aβ neurotoxici
More description
|
|
| DCC0637 | Ant3310 |
Novel Broad-Spectrum Serine β-Lactamase Inhibitor, Strongly Potentiating Meropenem Activity against Carbapenem-Resistant Enterobacterales and Acinetobacter baumannii
More description
|
|
| DCC0636 | Ant2681 |
Novel Metallo-β-lactamase Inhibitor with Potential for Clinical Use in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae
More description
|
|
| DCC0635 | Ansamitocins |
Antimitotic antibiotic with antitumor, antiprotozoal, and antifungal activities
More description
|
|
| DCC0634 | Annonin Vi |
Natural inhibitor of NADH:ubiquinone oxidoreductase
More description
|
|
| DCC0633 | Annh75 |
Novel Potent and Selective DYRK1 Kinase Inhibitor
More description
|
|
| DCC0632 | Annh31 |
Novel potent DYRK1A Kinase Inhibitor
More description
|
|
| DCC0631 | Ankaflavin |
Novel activator of nuclear factor-erythroid-related factor 2 (Nrf-2)
More description
|
|
| DCC0630 | Ank-199 |
Novel inducer of autophagic cell death through regulating PI3 kinase class III/beclin 1/Atg-related proteins in cisplatin-resistant CAR human oral cancer cells
More description
|
|
| DCC0629 | Angiotensin Acetate |
Peptide hormone that causes vasoconstriction and an increase in blood pressure
More description
|
|
| DCC0628 | Angiogenesis Agent C-30 |
Novel angiogenesis agent, showing better efficacy than salidroside in enhancing the accumulation of the HIF-1α protein and stimulating the paracrine functions of skeletal muscle cells, significantly increasing the angiogenic potential of vascular endothel
More description
|
|
| DCC0627 | Andrographolide Analogue 3a.1 |
Novel anticancer agent against metastatic Castration resistance and neuroendocrine variant prostate cancers (mCRPC/NEPC), exhibiting synergistic anticancer effect in combination with standard therapy docetaxel and cabazitaxel in mCRPC/NEPC, upregulating H
More description
|
|
| DCC0626 | And-302 |
Novel Potent Anticonvulsant Agent with In Vitro Neuroprotection
More description
|
|
| DCC0625 | Anacolin |
Anticholinergic agent
More description
|
|
| DCC0624 | An8799 |
Novel anti-filariasis agent, being effective in killing Brugia malayi, B. pahangi, and Litomosoides sigmodontis worms
More description
|
|
| DCC0623 | An3485 Hydrochloride |
Inhibitor of TLR2-, TLR3-, TLR4- and TLR5-mediated TNF-α, IL-1β and IL-6
More description
|
|
| DCC0622 | An3365 |
Novel potent and selective leucyl-tRNA synthetase inhibitor
More description
|
|